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ABSTRACT:
There is clinical and experimental evidence suggesting that antiprogestins might 
be used for the treatment of selected breast cancer patients. Our aim was to evaluate 
the effect of albumin-bound paclitaxel (Nab-paclitaxel) and pegylated doxorubicin 
liposomes (PEG-LD) in combination with mifepristone (MFP) in experimental breast 
cancer models expressing different ratios of progesterone receptor (PR) isoforms A and 
B. We used two antiprogestin-responsive (PRA>PRB) and two resistant (PRA<PRB) 
murine mammary carcinomas growing in BALB/c, GFP-BALB/c or nude mice, along 
with human T47D-YA and T47D-YB xenografts growing in immunocompromised NSG 
mice. MFP improved the therapeutic effects of suboptimal doses of Nab-paclitaxel or 
PEG-LD in murine and human carcinomas with higher levels of PRA than PRB. MFP 
induced tissue remodeling in PRA-overexpressing tumors, increasing the stromal/
tumor cell ratio and the number of functional vessels. Accordingly, an increase in 
nanoparticles and drug accumulation was observed in stromal and tumor cells in 
MFP-treated tumors. We conclude that MFP induces an increase in vessels during 
tissue remodeling, favoring the selective accumulation of nanoparticles inside the 
tumors. We propose that antiprogestins have the potential to enhance the efficacy 
of chemotherapy in breast tumors with a high PRA/PRB ratio. 
INTRODUCTION
Despite efforts to develop novel therapeutic 
anticancer agents to block specific signaling pathways, 
chemotherapy is still the gold standard for advanced 
breast cancer treatment. The challenge is to increase 
chemotherapeutic concentrations within the tumor 
environment while decreasing the general toxicity. 
Two drugs have been widely used: paclitaxel [1] and 
doxorubicin [2].
Paclitaxel is a diterpenoid product extracted from 
Taxus brevifolia [3] that causes G2/M cell cycle arrest 
by promoting microtubule assembly from tubulin and 
preventing microtubule depolymerization [4;5], inducing 
apoptosis through phosphorylation and downregulation 
of the anti-apoptotic proteins BCL-2 and BCL-XL 
respectively [6-9]. Because paclitaxel has very little 
aqueous solubility, a Cremophor /ethanol vehicle is used, 
but its toxicity limits the amount of paclitaxel that can 
be clinically administered [10-12]. To overcome this 
problem, an albumin-bound formulation of paclitaxel 
(Nab-paclitaxel) devoid of any solvents has been 
developed, and a better response was obtained with the 
latter when equitoxic doses of free or Nab-paclitaxel were 
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given [13;14]. 
Doxorubicin is a 14-hydroxylated version of 
daunorubicin, which is a natural product produced by 
wild type strains of Streptomyces [15]. The clinical 
usefulness of doxorubicin is limited due to dose-related 
progressive myocardial damage [16]. To overcome 
this drawback, different methods of drug delivery were 
developed, including pegylated liposomes. Due to the 
leaky vasculature of tumor vessels, pegylated liposomes 
preferentially distribute to tumors over normal tissue, thus 
decreasing the incidence rate of cardiotoxicity [17].
Two-thirds of breast cancers express hormone 
receptors and are subjected to endocrine therapy 
generally aimed at blocking estrogen receptors (ER) 
[18]. There is, however, compelling evidence suggesting 
that progesterone receptors (PRs) may also be used 
as therapeutic targets [reviewed in [19-20]. Most PR+ 
tumors express levels of PR isoform A (PRA) higher 
than those of isoform B (PRB) [21-25] and the 
presence of PRA may reduce the efficiency of taxanes 
on mammary tumor growth [26]. We have shown that 
murine mammary carcinomas with a high PRA/PRB 
ratio respond to antiprogestin treatment [27-29] and that 
this is characterized by an increase in stroma [30] and in 
metalloprotease activity [31]. 
We hypothesized that in PRA positive tumors, co-
treatment of antiprogestins may allow for the use of lower 
doses of chemotherapeutic agents thereby reducing their 
side effects. In this study, we show that mifepristone 
(MFP) treatment improves the therapeutic effect of 
pegylated doxorubicin liposomes (PEG-LD) and Nab-
paclitaxel by increasing tumor vascularization and thus the 
intratumoral concentration of nanotherapeutic particles.
RESULTS
Pegylated doxorubicin liposomes improve 
the therapeutic response compared to free 
doxorubicin
We first compared the therapeutic effect of PEG-
LD and free doxorubicin using MFP-responsive tumors 
of the medroxyprogesterone acetate (MPA)-induced breast 
cancer model (Figure 1). As shown in Figure 2 (top), 
PEG-LD at 18 and 9 mg/kg induced almost complete 
tumor regression and was more efficacious as compared 
with free doxorubicin as observed with the lower dose 
(p<0.05). Few tumor cells immersed in a dense stromal 
tissue were observed in PEG-LD treated tumors at the 
end of the experiment (Figure 2, bottom). However, with 
the highest dose (18 mg/kg), there were signs of toxicity, 
such as loss of body weight (Figure 3A) and palmoplantar 
erythrodysesthesia (not shown). Histologically, these 
PEG-LD-treated mice had specific skin lesions, with 
marked acanthopapillomatosis, hyperkeratosis and dermal 
fibrosis. We also observed mild cardiac hypertrophy. The 
other histological signs encountered were those typical 
of a cachectic state. The 9 mg/kg doses showed in a less 
degree some of the previously mentioned lesions. No other 
signs were found in mice receiving lower doses during the 
course of the experiments. These experiments indicated 
that even lower doses of PEG-LD should be selected for 
Figure 1: Tumors from the MPA-induced breast cancer model used in this study. Hormone-dependent mammary carcinomas 
induced by MPA are maintained by syngeneic passages in MPA-treated or untreated BALB/c mice. Occasionally hormone independent 
(HI) variants arise. These HI variants show different PR isoform ratios. C4-2-HI and 59-HI express higher levels of PRB than PRA and are 
resistant to MFP treatment (Western blots in the right panel). C4-HI and 59-2-HI show higher levels of PRA than PRB (Western blots in 
the left panel) and are MFP responsive tumors. These four tumors were selected for this study. The model is reviewed in Lanari et al., [32].
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Figure 2: Effect of PEG-LD and free doxorubicin on C4-HI tumor growth. Top: Growth curves. Syringes represent injections. 
With doses of 18 mg/kg, complete tumor regression was observed with both formulations. With doses of 9 mg/kg, PEG-LD showed an 
improved effect compared with free doxorubicin; a vs. b: p<0.05; ***: p<0.001 experimental vs. control. Bottom: histological images of 
tumors treated with 18 mg/kg PEG-LD for one month. Few residual neoplastic cells remained immersed in a dense hyaline stroma (arrow); 
bar = 100 μm.
Figure 3: Side effects of PEG-LD and Nab-paclitaxel. A. Changes in the body weights of BALB/c female mice after 4 weeks 
of PEG-DL treatment, with respect to their weights at day 0. Animals received iv four weekly doses (n=8). Only mice with the higher 
dose showed a significant decrease in body weight after treatment. B. Peripheral blood leukocytes in BALB/c mice treated once a week 
with different low doses of PEG-LD for three weeks. Control values were obtained before treatment initiation. Only the dose of 1.8 mg/
Kg induced a significant decrease (p<0.05) in the number of leukocytes/ml of blood. The rectangle represents the mean ± SD values 
observed in untreated mice. C. Nude mice were treated iv with three doses of Nab-paclitaxel, albumin or vehicle every four days. Animals 
were weighted at day 10 after treatment initiation. Only the dose of 60 mg/Kg induced a decrease in body weight. **: p<0.01 and p<0.05 
experimental vs. control group. 
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testing in combined treatment experiments.
MFP improved the therapeutic effect of PEG-
LD in murine mammary carcinomas with higher 
levels of PRA than PRB
We then evaluated the combination of low doses of 
PEG-LD (Doxopeg; 0.9 or 0.45 mg/kg) together with MFP 
in two MFP-responsive tumors expressing higher levels of 
PRA than PRB and in two MFP-resistant tumors with the 
opposite PR ratio (Figure 1). The doses of PEG-LD and 
MFP were fixed for each tumor to avoid complete tumor 
regressions. As shown in Figure 4A and 4B, the combined 
treatments showed improved effects compared with the 
single treatments only in MFP-responsive tumors (C4-HI 
and 59-2-HI). Histological images of C4-HI tumors at the 
end of the experiment are shown in Figure 4A (upper right 
panels). MFP induced differentiation and an increase in 
stromal tissue, as previously reported [28], while PEG-
LD increased necrosis. Few tumor cells surrounded 
by collagen fibers were observed with the combined 
treatments. In 59-2-HI, MFP induces an increase in the 
stroma/parenchyma ratio, decreases mitosis and increases 
apoptosis [30]. This tumor is so sensitive to MFP that we 
had to reduce the doses as much as 30 times as compared 
with that used for C4-HI tumors. PEG-LD at very low 
doses also relatively increased the stromal tissue, and 
epithelial cells with large bizarre nuclei were observed. 
Similar images with increased necrotic areas were seen in 
tumors with combined treatments (not shown).
C4-2-HI (Figure 4A lower panel) and 59-HI 
(Figure 4B, right) PEG-LD-treated tumors, in which PRB 
levels were higher than PRA, size and morphology were 
similar to those of combined treatments. The number of 
leukocytes remained within the control levels at these low 
PEG-LD doses (Figure 3B).
Figure 4: MFP improves the therapeutic effects of PEG-LD only in mammary carcinomas showing higher levels of 
PRA than PRB. A. left: C4-HI (top) or C4-2-HI (bottom) tumors were treated with PEG-LD (0.9 mg/kg) and/or MFP as described in 
Materials and Methods. An improved therapeutic effect was observed with combined treatments only in C4-HI tumors. Right, histological 
images of tumors excised after 28 days of treatment show that increased signs of tumor regression were observed with combined treatments 
only in C4-HI tumors; bar = 40 μm; ***: p<0.001 experimental vs. control; a vs. b or c: p<0.001. B. 59-2-HI (left) or 59-HI (right) 
tumors were treated with PEG-LD and/or MFP as described in Materials and Methods. An improved therapeutic effect was observed with 
combined treatments only in 59-2-HI tumors; ***: p<0.001 experimental vs. control; a vs. b or c: p<0.001. 
Oncotarget3250www.impactjournals.com/oncotarget
MFP improved the therapeutic effect of Nab-
paclitaxel in murine mammary carcinomas with 
higher levels of PRA than PRB
We first tested the effect of three doses of 60 and 
30 mg/kg of Nab-paclitaxel on body weight and tumor 
growth using tumors transplanted in nude mice (to avoid 
the potential immunogenic effect of the human albumin 
present in Nab-paclitaxel). Both doses induced a similar 
inhibitory effect on C4-2-HI tumor growth (Figure 5). 
Tumors disappeared almost completely after treatment, 
although they started growing back 10 days after the last 
dose. Only the dose of 60 mg/kg did induce a significant 
decrease in body weight (Figure 3C). The animals went 
back to their original weight within one week after the 
last dose of Nab-paclitaxel, and no specific histological 
alterations were found in autopsies of this group. 
We then studied the effect of Nab-paclitaxel (30 
mg/kg) on the growth of antiprogestin-responsive C4-
HI tumors. This dose did not significantly inhibit tumor 
growth. However, co-treatment with MFP improved 
the inhibitory effect induced by MFP (Figure 6A left). 
Selected animals were euthanized 10 days after treatment 
initiation). Nab-paclitaxel treatment induced aberrant 
mitotic figures and multiple hyperchromic nuclei 
(Figure 6A right). However, tumor histoarchitecture 
was essentially similar to that of the control tumors, 
and the tumors continued growing. MFP induced very 
early tumor differentiation, as expected [28], and MFP 
+ Nab-paclitaxel-treated tumors showed a differentiation 
pattern similar to that of MFP-treated tumors. The Nab-
paclitaxel signature was usually present shortly after 
treatment began, and giant cells with dense chromatin 
were frequently seen (Figure 6A, right). At the end of 
treatment, in most cases, more than 90 % of the tumor 
cells were lost (not shown). No additive effect was found 
in C4-2-HI tumors co-treated with Nab-paclitaxel (15 mg/
kg) and MFP (Figure 6B).
MFP improved the therapeutic effect of both 
PEG-LD and Nab-paclitaxel in T47D-YA but not 
in T47D-YB xenografts growing in NSG mice
MFP inhibited the growth of PRA-overexpressing 
xenografts, as expected (Wargon and Riggio et al, 
submitted). Nab-paclitaxel had an increased inhibitory 
effect on T47D-YB xenografts, while PEG-LD had it on 
T47D-YA tumors. We observed an improved therapeutic 
effect with combined treatments only in T47D-YA tumors 
(Figure 7A). Moreover, MFP lowered the inhibitory effect 
of Nab-paclitaxel in the T47D-YB tumors. Large amounts 
of collagen fibers were observed in all regressing tumors 
(Masson’s trichrome staining; Figure 7B). Cytokeratin 
(CK) staining (Figure 4C) revealed the relative amount 
of epithelial tumor cells in relation to the tumor mass, 
indicating that the therapeutic effect was even greater than 
Figure 5: Effect of Nab-paclitaxel on tumor growth. C4-2-HI tumors were transplanted into nude mice and treated with 60 or 30 mg/
kg Nab-paclitaxel as described in Materials and Methods. Tumors regressed with both Nab-paclitaxel doses. Albumin alone increased tumor 
growth. The histological images of tumors 28 days after treatment initiation are shown. Control tumors are composed by undifferentiated 
cells growing as solid sheets. Treated tumors show remaining tumor nests surrounded by stromal tissue; bar = 100 μm. Tumors regressed 
almost completely with both Nab-paclitaxel doses, and started to grow again 10 days after the last Nab-paclitaxel dose. ***: p<0.001 
experimental vs. both controls; p<0.05 control group vs. control with albumin. 
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Figure 6: MFP improves the therapeutic effects of Nab-paclitaxel only in mammary carcinomas showing higher levels 
of PRA than PRB. A. left: nude mice with palpable C4-HI tumors were treated as explained in Materials and Methods with Nab-
paclitaxel (30 mg/kg), MFP, or both treatments (n=6/group). MFP induced an inhibitory effect on tumor growth that was greater when 
combined with Nab-paclitaxel. ***: p<0.001 experimental vs. control; a vs. b or c: p<0.001. Right: Representative images of tumors 
excised 10 days after treatment initiation. Nab-paclitaxel induced an early increase in aberrant cells with multinucleated pleomorphic 
nuclei showing partially condensed chromatin. The inset shows a tetrapolar mitosis (arrow head) and a mitotic cell with chromosomal 
spreading (arrow). Eosinophilic cells and cells with large amounts of cytoplasm were also encountered. MFP induced differentiation. In 
(Nab-paclitaxel+MFP)-treated tumors, the combined treatment mimics the effect of antiprogestin, although a higher number of aberrant 
signet ring-like cells can be observed (inset). B. left: Nab-paclitaxel (15 mg/kg) inhibited the growth of C4-2-HI, and MFP did not improve 
the effect of Nab-paclitaxel. Right: No morphological differences were observed in C4-2-HI tumors with the combined treatments. Bar = 
40 μm; inset bar = 20 μm. 
Figure 7: MFP improves the therapeutic effects of PEG-LD and Nab-paclitaxel only in xenografts overexpressing 
PRA. A. T47D-YA or T47D-YB xenografts growing with E
2
 in NSG mice (n=6/group) were treated with PEG-LD (0.9 mg/kg) or Nab-
paclitaxel (15 mg/kg) and/or MFP (10 mg/kg/day). MFP only inhibited the growth of T47D-YA xenografts; PEG-LD was more effective 
in T47D-YA tumors compared to T47D-YB tumors, and the latter were more sensitive to Nab-paclitaxel than T47D-YA tumors. Improved 
effects with combined treatments were only observed in the T47D-YA tumors. ***: p<0.001; **: p<0.01; and *: p<0.05 (experimental vs. 
control). T47D-YA, top a vs. b: p<0.05; a vs. c: p<0.001; bottom: a vs. b or c: p<0.05. T47D-YB, bottom: a vs. b: p<0.05; a vs. c: p<0.001. B. 
Masson’s trichrome staining. High levels of collagen (blue fibers) can be observed in all regressing tumors. C. CK staining. The amount of 
epithelial cells (CK+) in relation to the total number of cells can be observed. Few epithelial tumor cells remain after combined treatments 
in T47D-YA tumors. Conversely, for T47D-YB, the best therapeutic option was Nab-paclitaxel. Bar = 40 μm. 
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expected based on the values obtained by measuring the 
tumors. Interestingly, T47D cells grow invading muscle, 
nerves or grow inside the mammary gland ducts, and the 
latter were protected from the chemotherapeutic effects of 
the drugs (Figure. 8).
MFP modifies the microenvironment and 
microvasculature of responsive tumors, inducing 
an increase in nanoparticle accumulation
C4-HI regresses under antiprogestin treatment by 
increasing differentiation and stromal tissue production 
(Figure 6A top), and 59-2-HI regresses by increasing the 
stroma/parenchyma ratio (Figure 9A). Using the 59-2-
HI tumor, we explored whether MFP induced a change 
in the number of vessels. An increase in the number of 
CD31-positive cells (endothelial cells) was observed in 
MFP-treated tumors (Figure 9B). In addition, fluorescent 
tomato lectin (TL), which binds to endothelial cells, was 
injected in vivo as described in Materials and Methods, 
and an increase in staining was observed in MFP-treated 
tumors (Figure 9C). Co-localization between CD31 and 
TL confirmed the increase in vessel functionality in MFP-
treated tumors (Figure 9D). 
To evaluate whether this increased vascularization 
could be responsible for an increase in drug accumulation, 
count control Fluorescent Beads for Flow Cytometry 
(FB) or purified red blood cells (RBC) obtained from 
transgenic mice expressing enhanced Green Fluorescent 
Protein (GFP) under the direction of the human ubiquitin 
C promoter (GFP-RBC) were injected iv into mice bearing 
tumors that were treated or not with MFP, and their 
presence inside the tumors was quantified by FACS. An 
increase in FB (Figure 10A) or GFP-RBC (Figure 10B 
and 10C) was found in the tumors from MFP-treated mice, 
while no differences were found in the GFP-RBC content 
in their spleens (Figure 10B).
Next, we took advantage of doxorubicin’s red 
autofluorescence. Tumors growing in BALB/c-GFP mice 
were treated as described in Materials and Methods. As 
shown in Figure 11A, red nuclear staining was observed 
in stromal cells and in the tumor cells adjacent to them 
(green cells). The total amount of doxorubicin was much 
Figure 8: Images of T47D-YA and T47D-YB cells growing in vessels, muscle or nerve fibers, or inside the mammary gland 
ducts. Top panel: T47D-YA tumor cells (CK+) invading muscle fibers (A), or growing inside an alveolar structure of the mammary gland 
(B; H&E), C. Images of PEG-LD treated-tumors. Red arrow shows small groups of remaining CK+ tumor cells surrounded by stromal 
tissue. Black arrow shows tumor cells growing inside a ductal structure. Bottom panel: T47D-YB tumor cells growing in between the 
muscle skeletal fibers (D), or lining the wall of a vessel (E). F. Perineural invasion of cells growing surrounding a nerve fiber. Black arrow: 
nerve sheath. Red arrow: tumor cells in the perineural space. An antibody that only recognizes human CK was used. Bar = 20 μm.
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Figure 9: MFP treatment increased tumor remodeling and the amount of functional vessels in mammary carcinomas 
showing higher levels of PRA than PRB. A. 59-2-HI tumors growing in BALB/c-GFP mice were treated or not for 5 days with MFP 
(10 mg/kg/day). An increase in stromal cells (green cells; GFP) was observed in MFP-treated tumors. Nuclei were counterstained with PI 
(red); bar = 300 µm. B. Similar experiments with tumors growing in BALB/c mice. An increase in CD31 positive cells (green staining; 
FITC) was observed in MFP-treated tumors. Nuclei were counterstained with PI; bar = 300 µm. C. TL were iv injected in mice bearing 
tumors treated as described in B. Mice were euthanized and tumors processed for IF studies. PI was used for nuclear staining. Increased 
total lectin fluorescence (green) was observed in MFP-treated tumors; bar = 300 µm. D. Co-localization between TL (green) and CD31 
immunostaining (red). Increased co-localization was observed in MFP-treated tumors (yellow); left bar = 300 µm; right bar = 50 µm. 
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Figure 10: MFP increased the amounts of FB or GFP-RBC in tumors with higher levels of PRA than PRB. A. FACS 
analysis of FB injected iv in MFP-treated tumors and untreated mice bearing 59-2-HI tumors. Sixty minutes later mice were euthanized and 
tumors processed for FACS analysis. An increase in FB was observed in MFP-treated tumors. B, FACS analysis of GFPRBC injected as in 
A. GFP-RBC were prepared as described in Materials and Methods and were inoculated iv in MFP-treated or untreated tumor bearing mice. 
Top panel: FACS analysis of GFP-RBC (positive control) and middle panel negative control. Bottom panels: the content of GFP-RBC was 
evaluated after 3 days by FACS analysis in tumor tissue or in spleens. An increase of GFP-RBC was observed in tumors and not in spleens 
from MFP-treated mice as compared with untreated mice. *: p<0.05; **: p<0.01 and ***: p<0.001. Frequency corresponds to the number 
of GFP-RCB (P1) gated on the erythrocyte population in the FAC-A vs. the SSC-A dot plot.
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higher in the tumors subjected to the combined treatments. 
No differences were observed in similarly treated C4-2-HI 
tumors (Figure 11B).
Similarly, the amount of Nab-paclitaxel present in 
the tumors was indirectly evaluated using a polyclonal 
anti-human albumin antibody. Increased staining was 
found in animals subjected to combined treatments (Figure 
11C). No staining was observed in the negative controls.
DISCUSSION
In this study we show that mammary carcinomas 
expressing different ratios of PR isoforms are sensitive to 
both PEG-LD (anthracycline) and Nab-paclitaxel (taxane). 
Antiprogestin-resistant tumors were very sensitive to Nab-
paclitaxel, whereas tumors with higher levels of PRA than 
PRB were less sensitive (C4-HI vs. C4-2-HI and T47D-
YA vs. T47D-YB). The opposite result was observed 
Figure 11: MFP increased the amounts of PEG-LD or Nab-paclitaxel in tumors with higher levels of PRA than PRB. 
A. 59-2-HI tumors were transplanted in BALB/c-GFP mice and were treated or not with MFP as described in Figure 5. PEG-LD (18 mg/
kg) were injected iv and after 24 h tumors were excised and processed for confocal microscopy studies. The red staining corresponds 
to the doxorubicin autofluorescence. Notice the red staining in stromal cells (orange; fill arrow) and in epithelial tumor cells nearby the 
stromal cells; top bar = 120 μm, bottom bar = 30 μm; B. C4-2-HI tumors were similarly treated and no differences in doxorubicin content 
were observed between treated and untreated tumors; bar = 120 μm. C. Tumors growing in nude mice were treated with MFP as described 
above and Nab-paclitaxel (60 mg/kg) was injected iv. After 24 h tumors were excised and processed for IF studies. An anti human albumin 
antibody and a FITC-coupled secondary antibody (green) were used. PI was used for nuclear counterstaining. No staining was observed 
in negative controls (treated without primary antibodies or in untreated tumors); bar = 120 μm *: p<0.05; **: p<0.01 and ***: p<0.001.
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with PEG-LD treatment. Targeting PRA-overexpressing 
tumors with antiprogestins resensitized the tumors to both 
chemotherapeutic treatments.
Because chemotherapy is the therapy of choice 
for metastatic breast disease, an ideal scenario would 
be to improve its efficacy by specifically increasing 
the delivery into tumor cells, thus reducing potentially 
deleterious side effects associated with normal tissue 
targeting. Nab-paclitaxel accumulates in cancer cells due 
to their increased ability to engulf albumin [32]. Pegylated 
liposomes are also concentrated in tumor cells because of 
the leaky tumor vasculature [16]. Antiprogestin treatment 
may increase the efficiency of these highly selective 
agents in a subgroup of breast cancer patients: those 
overexpressing PRA. 
To explain the potential mechanisms involved in 
this increased efficacy, we examined several possibilities. 
It has been reported that MFP and progesterone are able 
to bind multidrug-resistant proteins and thus improve the 
entry of chemotherapeutic agents into the cells [33;34]. 
Although this may be a very interesting possibility to 
explore, it does not seem to be the prevailing mechanism 
because almost complete tumor regressions were observed 
with anthracyclines in this model (Figure 2A), which is a 
response that is not compatible with a multidrug resistance 
mechanism. Therefore, we explored the possibility 
that the tissue remodeling induced by antiprogestin 
treatment could be responsible for the drug accumulation. 
Accordingly, it has been demonstrated that the therapeutic 
effects of doxorubicin were decreased in KO mice lacking 
MMP-9 [35], and interestingly, MMP-9 expression is 
increased in tumors of the MPA breast cancer model 
treated with MFP [31]. 
Using endothelial markers, we showed an increase 
in the number of capillary-type vessels within the tumor. 
This result, although counterintuitive at first, also negates 
the idea that diminished angiogenesis might play a role 
in MFP-induced tumor regression. Conversely, these 
new functional vessels participate in the distribution 
of the chemotherapeutic drugs within the tumor. A 
proangiogenic effect may be the direct outcome of 
an initial hypoxic state induced by the first dose of the 
chemotherapeutic agent. However, since MFP alone 
induces apoptosis, necrosis and/or cytostasis in the tumor 
parenchyma of PRA-overexpressing tumors, it seems 
likely that this increased angiogenesis is driven by non-
specific stromal changes, secondary to epithelial cell 
death. The mechanisms that trigger these effects deserve 
further investigation. Our results are in agreement with 
those reported by Nakasone et al., who found that free 
doxorubicin accumulates in cells flanking tumor vessels 
in two different transgenic mouse models [35]. In support 
of the remodeling hypothesis, we also demonstrated that 
estrogen treatment, which also induces tumor regression 
in this model [36], is also able to increase the therapeutic 
effect of these chemotherapeutic drugs (data not shown). 
Other drugs have also been proposed to alter the tumor 
microenvironment such as hialuronidase that improved 
the access of PEG-LD in osteosarcoma xenografts [37], or 
losartan, an angiotensin receptor inhibitor that inhibits the 
synthesis of collagen type I present in desmoplastic tumors 
[38]. Losartan improved the therapeutic effect of 4 mg/kg 
PEG-LD, which is a suboptimal chemotherapeutic dose 
that is 4 times higher than the doses used in our assays. 
The doses of PEG-LD used is our study ranged from 18 
mg/kg (equivalent to a human dose of 54 mg/m2) to 0.45 
mg/kg (equivalent to 1.85 mg/m2)[39]. For breast cancer 
treatment a dose of 50 mg/m2 is recommended.
Our studies also suggest that anthracyclines may be 
a better option than taxanes for the treatment of tumors 
overexpressing PRA, while taxanes may be better for those 
expressing PRB. The reason for this selectivity is still not 
known. For paclitaxel, it can be speculated that PRA-
overexpressing tumors have increased levels of BCL-XL 
or BCL-2 than their PRB counterparts [40]; alternatively, 
they may have increased levels of other proteins related 
to microtubule assembly that are oppositely regulated 
by taxanes [26]. An excess of these proteins may be 
decreasing paclitaxel efficacy. 
Some of the histopathological observations 
regarding the paclitaxel effect may deserve further 
investigation. We are currently exploring the biological 
consequences that the presence of aberrant mitosis may 
have in tumors that are not growth inhibited by paclitaxel 
at doses of 30 mg/kg such as C4-HI. These observations 
may have clinical relevance, as they indicate that paclitaxel 
treatment should be potent enough to destroy the majority 
of proliferating cells, thus avoiding the selection of more 
aggressive phenotypes. In the same line, it has been 
recently reported that paclitaxel may increase polyploidy 
and therefore alter the status of erbB2 expression [41]. 
There are several reports regarding the effect of 
combined chemotherapeutic treatments and endocrine 
therapies. In preclinical studies involving fulvestrant 
or tamoxifen, it has been shown that fulvestrant exerts 
synergic effects with other chemotherapeutic agents 
under experimental conditions in which tamoxifen failed 
[42]. In clinical studies in which combined or sequential 
adjuvant tamoxifen and chemotherapy were compared, 
no beneficial effects were observed with combined 
treatments [43]. Hypotheses predicting an additive or 
synergistic effect, such as reversal of p170-mediated 
resistance to anthracyclines by tamoxifen, appeared 
not to play a clinically relevant role. The most accepted 
explanation for this failure was that tamoxifen decreased 
the number of proliferating cells, thus creating cytokinetic 
resistance to chemotherapy. It can be hypothesized that 
in the absence of a significant tumor mass, as occurs in 
adjuvant therapies, the remodeling effect of endocrine 
therapy described in this study does not take place. 
Accordingly, the mechanisms we describe here may 
synergize with those of chemotherapeutic agents delivered 
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as nanoparticles in combination with an endocrine therapy, 
while lowering potential side effects. We expect that in the 
near future, antiprogestins might be an option for breast 
cancer patients overexpressing PRA. 
Interestingly, Skor et al [44] reported that MFP 
increased the efficiency of paclitaxel in triple negative 
xenografts, thus counteracting the protective effect that 
glucocorticoid receptors (GR) exert on chemotherapy. 
Because these results indicate a beneficial effect of MFP 
in combination with paclitaxel, it may be argued that 
GR might also be playing a similar role in our studies. 
However, the fact that T47D-YA and T47D-YB xenografts 
only differ in the introduced PR isoform and that only 
the T47D-YA xenografts showed improvement with 
combined therapies suggests that this is not the prevailing 
mechanism.
In summary, we propose that breast cancer patients 
with advanced disease should be categorized according to 
the prevailing PR isoform expressed. For those expressing 
high levels of PRA, the combination of an antiprogestin 
together with a chemotherapeutic agent may allow for 
the use of lower chemotherapeutic doses, mainly in neo-
adjuvant protocols, thus improving the quality of life.
MATERIALS AND METHODS
Animals
Two-month-old virgin female BALB/c mice 
(Animal Facility, IBYME) were used. Transgenic mice 
expressing enhanced Green Fluorescent Protein (GFP) 
under the direction of the human ubiquitin C promoter 
(The Jackson Laboratories, Bar Harbor, Maine) were bred 
at IBYME (BALB/c-GFP). Nu/nu females were obtained 
from the University of La Plata and NOD/LtSz-scid/IL-
2Rgamma null mice (NSG) from The Jackson Laboratory 
and bred at IBYME. Animal care and manipulation were 
in agreement with the Guide for the Care and Use of 
Laboratory Animals [45]. 
Tumors and xenografts
C4-HI, C4-2-HI, 59-HI or 59-2-HI carcinomas from 
the MPA-induced murine breast cancer model [46], all 
expressing ER and PR, were orthotopically transplanted 
into the mammary gland 4 of BALB/c, BALB/c-GFP or 
nu/nu mice. C4-HI and 59-2-HI tumors regress with MFP 
treatment and express levels of PRA higher than those of 
PRB; C4-2-HI and 59-HI are constitutive MFP-resistant 
tumor variants with levels of PRB higher than those of 
PRA (Figure 1) [28]. T47D-YA and T47D-YB cells were 
a kind gift of Dr. K. Horwitz (University of Colorado) 
and were cultured as previously described [47]. Cells 
(5x106) were inoculated orthotopically into NSG female 
mice. One week prior to cell inoculation, E
2
 silastic pellets 
containing 0.5 mg 17-βestraciol (E
2
) were subcutaneously 
(sc) implanted [48].
Treatments
Free doxorubicin and the PEG-LD Doxopeg 
were a kind gift of Laboratorios Raffo (Buenos Aires) 
whereas Nab-paclitaxel Abraxane (Abraxis Bioscience) 
is a commercial preparation. PEG-LD vehicle and 
free human albumin, provided by Laboratorios Raffo, 
were used as a control in PEG-LD or Nab-paclitaxel 
experiments respectively. PEG-LD or doxorubicin were 
administered intravenously (iv) in a range of 18-0.45 mg/
kg body weight once a week. For the highest dose we 
used a protocol adapted from Charrois and Allen [49]. 
Three consecutive doses of 60, 30 or 15 mg/kg of Nab-
paclitaxel were given iv every 4 days [50]. MFP (Sigma, 
St Louis, MI) was administered using 6 or 0.2 mg pellets 
implanted subcutaneously (sc) or by sc daily injections of 
10 mg/kg body weight. Tumor size was evaluated using a 
Vernier caliper. Mice were euthanized, and transplanted 
tumors and metastases were fixed in buffered formalin 
and embedded in paraffin. Five microns sections were 
used for histological diagnoses (H-E staining and Masson 
trichrome). The pathological response to treatments was 
assessed according to Miller and Payne grading system 
[51]. To evaluate the intra tumor drug content, mice were 
treated for 5 days with MFP, and then with Nab-albumin 
or PEG-LD for 24 hours. 
Side effects
Mice without tumors (6-8 per group) were treated as 
described above, and weighed once a week (PEG-LD) or 
every four days (Nab-paclitaxel). PEG-LD-treated mice 
were sacrificed after one month and Nab-paclitaxel-treated 
mice after 10 days of treatment. For leukocyte counting, 
PEG-LD was administered once a week and mice were 
bled 3 times a week during 20 days (n=8). Leukocytes 
were counted using the analyzer Ac T diff of Coulter.
Immunofluorescence
Frozen tumor sections (15 µm) were fixed in 
10% formalin, transferred to 70% ethanol, blocked, and 
successively incubated overnight with CD31 (550274, 
BD Pharmingen) or with anti human albumin (ab2406; 
Abcam), antibodies and processed as described previously 
(32). The nuclei were counterstained with propidium 
iodide (PI) and analyzed using a Nikon Eclipse E800 
confocal Microscope. Images were taken with a Nikon 
DS-U1 camera with ACT-2U software. BALB/c-GFP mice 
were perfused with a cold saline solution (0.9% NaCl) 
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followed by 4% paraformaldehyde before tumor excision. 
Excised tumors were kept in cold 4% paraformaldehyde 
overnight and transferred to 20% sucrose for another 24 
hours. Endogenous doxorubicin or GFP fluorescence were 
analyzed by confocal microscopy. 
Immunohistochemistry
 It was carried out as described previously [30] 
using the CK antibody from Dako (clone AE1/AE3).
Quantification of Stroma, TL, Count control Fluorescent 
beads for Flow Cytometry (FB) or GFP-red blood cells 
(RBC)TL (70 µl of a 20 mg/ml solution; Vector Labs, 
Burlingame, CA), FB (3.5 x 106; S236630, Dako) or 
purified GFP-RBC (6 x 106) [52] were injected iv into 
MFP-treated or untreated mice bearing tumors. After 7 
(TL) or 60 minutes (FB), or 72 hours (RBC), the mice 
were euthanized and tumors processed for confocal 
microscopy (TL) or flow cytometry (FB and GFP-RBC). 
Statistical analysis
GraphPad Prism (version 5.0) was used for 
statistical analysis. ANOVA and Bonferroni multiple 
post t tests were used to evaluate differences of means 
of multiple samples, and Student’s t test of two different 
groups. Tumor growth curves were studied using 
regression analysis and slopes compared using one-way 
ANOVA followed by parallelism analysis. In all graphs, 
the mean ± SEM is shown. Experiments were repeated at 
least twice.
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